| Business Summary | | Paligent,
Inc.,
together
with
its
subsidiaries,
is
currently
engaged
in
evaluating
strategic
alternatives
for
its
business.
From
its
inception
in
1985
through
1999,
the
Company
operated
as
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
novel
drugs
with
a
product
portfolio
focused
on
infectious
diseases
and
oncology.
In
March
1999,
the
Company
acquired
Pacific
Pharmaceuticals,
Inc.
(Pacific),
a
company
engaged
in
the
development
of
cancer
therapies.
In
January
2000,
the
Company
consummated
a
major
strategic
change
in
its
business
by
acquiring
Heaven's
Door
Corporation
(HDC),
a
company
that
provided
business-to-business
and
business-to-consumer
products
and
services
for
the
funeral
service
industry
over
the
Internet. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Paligent,
Inc.
is
currently
engaged
in
evaluating
stratgeic
alternatives
to
maximize
value
to
existing
stockholders.
For
the
six
months
ended
6/30/01,
revenues
fell
60%
to
$53
thousand.
Net
loss
fell
97%
to
$737
thousand.
Revenues
reflect
a
reduction
in
interest
income
due
to
a
decrease
in
average
cash
balances
available
for
investments.
Lower
loss
reflects
the
closure
of
Company's
R&D
facility
and
a
reduction
in
stock
based
compensation
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Weiss, 34 Chairman,
Sec. | -- | Salvatore Bucci, 45 Pres,
CEO | $110K | John Dee, 43 Vice
Chairman | 111K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|